Novo Holdings Portfolio Company F2G enters strategic collaboration with Shionogi to commercialise its new antifungal agent Olorofim in Europe and Asia
Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.
- Novo Ventures, the venture capital team at Novo Holdings, has led and participated in a series of financings since 2016.
- Naveed Siddiqi, Senior Partner at Novo Holdings, serves as a Board Member of F2G and Eric Snyder, Partner at Novo Holdings, as Board Observer.
- Olorofim is a novel oral antifungal therapy developed by F2G to treat invasive aspergillosis (IA) and other rare mold infections.
- Novo Holdings A/S is a private limited liability company wholly owned by the Novo Nordisk Foundation.